A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations

A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations
It's a beautiful painting but it's just too depressing to hang anywhere. When she died, she left me the painting and it hangs in a place of honor over my fireplace mantle. It was painted in 1988 by Reverend Howard Finster and is done in vibrant colors and also depicts the buildings in the market like an ice cream parlor and the Hotel Van Nuys. I don't know whose smile is bigger, the one in the painting or the one on my face every time I look at it.The painting that has touched me the most features a sad little girl and is called A Letter From My Mother. I saw a painting he did of a fishing scene but I chose not to buy it. It's called Alligator Fisher and I'm thinking about getting because it reminds me of my cajun heritage, most of my family is from Louisiana. It's too bad my parents didn't let her play football with the boys and I used to tease her relentlessly and pull her pigtails whenever I got the chance.I have loved folk art paintings since I was a child. She favors animal prints, and I found one that depicts leopards and gave it to her for her birthday. Now we're very close. It's of a swamp house on a bayou and has a Louisiana feel to it. Still, they are a joy to behold. Maybe it's because I spent a lot of time playing in my tree house, that the trees in the picture appealed to me so much. I don't particularly care for his art. One of my favorites that she had was done by John Roeder. I'll find someone to give it to..One of my favorite paintings was done in 1962 by Bill Dodge.Another painting that I admire is.....

Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones).D. The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. This gel acts as a depot that slows drug escape from the knee cavity." Additional References Citations A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. This research was presented Oct. This research was presented Oct., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint.D.In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. It is projected to affect more than 20 percent of the U.Osteoarthritis affects 30 million Americans and is the most common joint disorder.A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. This research was presented Oct. This research was presented Oct., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint.D.In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules I don't know whose smile is bigger, the one in the painting or the one on my face every time I look at it. I don't particularly care for his art. It was painted in 1988 by Reverend Howard Finster and is done in enamel. It's called Alligator Fisher and I'm thinking about getting because it reminds me of my cajun heritage, most of my family is from Louisiana. She favors animal prints, and I found one that depicts leopards and gave it to her for her birthday. If she could kick the ball they way she liked to kick me in the knee, I'd see to it she played for my team every time.There is a subcategory of folk art paintings that depict the world of black Americans. I spent a lot of time playing in my tree house, that the trees in the picture appealed to me so much. Now we're very close.My sister also shares my love for folk art. I have a friend who collects these and I found one of a woman reclining in a hammock.One of the most famous American artists is Thomas Chambers. I personally don't have any of these in my collection, since I like to collect pieces that I can relate to.Another painting that I admire is called Howard in 1944. When she died, she left me the painting and it hangs in a place of honor over my fireplace mantle. I saw a painting he did of a fishing scene but I chose not to buy it. It's a beautiful painting but it's just too depressing to hang anywhere. It's pretty funny to me that when we were growing up, she'd cry because she wasn't allowed to play football with the boys and I used to tease her relentlessly

rthritis drug athritis drug arhritis drug artritis drug arthitis drug arthrtis drug arthriis drug arthrits drug arthriti drug arthritis rug arthritis dug arthritis drg arthritis dru srthritis drug aethritis drug atthritis drug arrhritis drug aryhritis drug artgritis drug artjritis drug artheitis drug arthtitis drug arthrutis drug arthrotis drug arthriris drug arthriyis drug arthritus drug arthritos drug arthritia drug arthritid drug arthritis srug arthritis frug arthritis deug arthritis dtug arthritis dryg arthritis drig arthritis druf arthritis druh rathritis drug atrhritis drug arhtritis drug artrhitis drug arthirtis drug arthrtiis drug arthriits drug arthritsi drug arthriti sdrug arthritis rdug arthritis durg arthritis drgu arthritis dru aarthritis drug arrthritis drug artthritis drug arthhritis drug arthrritis drug arthriitis drug arthrittis drug arthritiis drug arthritiss drug arthritis ddrug arthritis drrug arthritis druug arthritis drugg
A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations

A novel study demonstrates that using nanoparticles to deliver osteoarthritis drugs to the knee joint could help increase the retention of the drug in the knee cavity, and therefore reduce the frequency of injections patients must receive. This research was presented Oct. 23 - 27 at the 2011 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in Washington, D.C.

Osteoarthritis affects 30 million Americans and is the most common joint disorder. It is projected to affect more than 20 percent of the U.S. population by 2025. Aging, obesity and joint injury can lead to osteoarthritis, which is characterized by progressive erosion of articular cartilage (cartilage that covers the bones). The disease can occur in all joints, most often the knees, hips, hands and spine, and currently there are no pharmacological treatments that halt the disease progression. For large joints, a drug could be injected into the joint to help limit potential side effects, like pain. A significant challenge in treating osteoarthritis this way is the short duration the medicine stays in the affected joint after injection.

Lead researcher Michael Morgen, Ph.D., and his colleagues from Bend Research and Pfizer propose to address this challenge with injectable nanoparticles that help retain osteoarthritis drugs in the knee joint. Test results show that 70 percent of the drug nanoparticles remain in the knee cavity after one week. In contrast, for most current formulations, the drug disperses within one to two days.

In this new process, positively charged nanoparticles carrying a drug attach to the negatively charged, naturally occurring molecules in the knee to form a gel. This gel acts as a depot that slows drug escape from the knee cavity.

"Current delivery methods do not maintain the drug in the knee for very long, which limits the effectiveness of therapeutic agents," said Dr. Morgen. "We hope that this type of sustained release technology, when used with current or new osteoarthritis drugs, will allow patients to be effectively treated with drug injections every three months instead of once a week."

  • Additional
  • References
  • Citations